matthew lee - Male - United States » WIMKIN

matthew lee shared

August 6, 2025 1:04 pm

Jase shared a photo

July 30, 2025 5:44 pm

FOR IMMEDIATE RELEASE – READ BELOW - MULTIPLE ANNOUNCEMENTS Rejuvenalt Bioscience Corp. and Ecnalab LLC Announce Strategic Merger to Accelerate Innovation and Shareholder Value July 30, 2025 – San D... View MoreFOR IMMEDIATE RELEASE – READ BELOW - MULTIPLE ANNOUNCEMENTS Rejuvenalt Bioscience Corp. and Ecnalab LLC Announce Strategic Merger to Accelerate Innovation and Shareholder Value July 30, 2025 – San Diego, CA — Rejuvenalt Bioscience Corp. (“Rejuvenalt”), an innovator in next-generation biotechnology solutions without the toxicity, side effects, or profiteering embedded in conventional pharmaceutical models, and Ecnalab LLC (“Ecnalab”), the founders of The Fentanyl Test, are pleased to announce the execution of a definitive Agreement and Plan of Merger. The agreement provides for the merger of Ecnalab with and into Rejuvenalt, with Rejuvenalt continuing as the surviving corporation. Under the terms of the merger, Ecnalab members will receive 250 shares of Rejuvenalt common stock for each Ecnalab membership unit held, resulting in the issuance of 2,500,000 shares and giving Ecnalab shareholders a 25% stake in the combined company. Key Benefits to Ecnalab Shareholders: Significant Equity Participation: Ecnalab shareholders will collectively own a quarter of Rejuvenalt’s post-merger capital structure, ensuring substantial participation in future value creation. Ecnalab Unit value was $500 per unit. The projected value of the 250 Rajuvenalt shares to be received is $2500. Save more lives. The new company will focus on saving lives by providing our life saving tests and revolutionizing medicine by offering holistic, regenerative therapeutics and nutraceuticals that not only address the root causes of disease but restore the body's innate ability to heal itself—without the toxicity, side effects, or profiteering embedded in conventional pharmaceutical models. Liquidity and Market Visibility: Rejuvenalt’s corporate structure and growth trajectory position the combined entity for potential capital market access and broader investor visibility. Enhanced Resources and Synergies: The merger aligns Ecnalab’s R&D capabilities with Rejuvenalt’s commercial infrastructure and regulatory experience, enabling faster product development and market penetration. Board Representation: Ecnalab shareholders will have direct influence in corporate governance through board representation, ensuring their interests remain central in strategic decisions. “This merger is a win for our members,” said Ecnalab CFO John Alduenda. “By joining forces with Rejuvenalt, we are unlocking growth potential far beyond what we could have achieved independently. Our innovative science will now be supported by greater capital, expanded expertise, and a unified vision.” The merger, approved unanimously by both companies’ governing bodies, is expected to qualify as a tax-free reorganization under Section 368(a)(1)(A) of the Internal Revenue Code. The transaction is expected to close following customary regulatory filings with the California Secretary of State. In Parallel News: WIMKIN Announces Major Strategic Developments WIMKIN, our fast-growing free speech social media platform, has announced a strategic partnership with Stock Traders Daily, giving our Users access to world class market insights at hugely discounted rates, aligning efforts to amplify financial transparency, investor outreach, and platform monetization. WIMKIN is also proud to announce plans to go public, giving its users and shareholders the opportunity to participate in the company's long-term growth and mission through public markets. As part of its monetization and user privacy strategy, WIMKIN users will soon have a new choice in how their data is handled: Free Membership: Continue enjoying all platform features with advertising support. Secure Membership: For just $1.99 per month, users can opt-out of data sharing, enjoy an ad-free experience, and help protect their personal information—all for less than the price of a cup of coffee. WIMKIN Influencers will benefit too, earning $50 per month for every 5,000 friends, recognizing the value of their truth-driven engagement. Here at WIMKIN, We’ve always believed in information without filters. With these changes, we’re staying true to our mission while increasing resources to grow the platform and reward our community. Value to WIMKIN Shareholders: Increased working capital Enhanced platform valuation Scaled influencer programs Improved privacy protections Pre-IPO momentum and trading liquidity opportunities WIMKIN users, influencers, and shareholders alike will benefit from these transformative steps as the company evolves to meet growing demand while protecting the freedom of speech and conservative values that define its mission. Media & Investor Contacts: Email: Jalduenda@thefentanyltest.com Users, Influencers & Shareholder Q&A: Section 1: Merger Between Rejuvenalt Bioscience Corp. and Ecnalab LLC Q1: What is happening between Rejuvenalt and Ecnalab? A: Rejuvenalt Bioscience Corp. and Ecnalab LLC have entered into an Agreement and Plan of Merger. Ecnalab will be merged into Rejuvenalt, with Rejuvenalt continuing as the surviving corporation. Q2: What do I get as a shareholder/member of Ecnalab? A: Each Ecnalab membership unit will convert into 250 shares of Rejuvenalt common stock. If you hold 100 units, for example, you will receive 25,000 Rejuvenalt shares. Q3: What percentage of the new company will Ecnalab shareholders own? A: Ecnalab shareholders will collectively own 25% of Rejuvenalt’s total outstanding shares after the merger. Q4: What are the benefits of this merger for Ecnalab shareholders? A: Key benefits include: Ownership in a larger, growth-oriented biotech company Enhanced access to capital and commercialization pathways Representation on the Board of Directors A more liquid equity structure compared to LLC membership units Q5: Will there be changes to leadership or governance? A: Yes. Ecnalab shareholders will designate a representative to join the Rejuvenalt Board of Directors, ensuring shareholder interests are reflected in strategic decisions. Q6: What happens to Ecnalab as a legal entity? A: Ecnalab will cease to exist as a separate LLC and will be fully absorbed into Rejuvenalt. Q7: Is this a taxable event for me? A: The merger is structured to qualify as a tax-free reorganization under Section 368(a)(1)(A) of the Internal Revenue Code. You should consult your tax advisor to understand implications specific to your situation. Q8: Is Rejuvenalt planning to go public? A: The company is actively evaluating pathways for going public, including a potential initial public offering (IPO) or direct listing. No final decision has been made yet. Q9: What does going public mean for me as a shareholder? A: If Rejuvenalt goes public: Your shares may become tradable on a public stock exchange (e.g., NASDAQ). You could potentially realize liquidity by selling shares. You may be subject to lock-up periods or transfer restrictions, depending on the structure of the offering. Q10: Will my shares be diluted in an IPO? A: An IPO typically involves the issuance of new shares, which may dilute existing ownership. However, this dilution is generally offset by increased company valuation and public market access. Q11: Will I need to take any action as part of the IPO process? A: You may be asked to sign updated shareholder agreements or lock-up agreements. You will also receive instructions on how your shares will be converted or registered for public trading, if applicable. Q12: Will there be more transparency and reporting requirements after going public? A: Yes. Public companies are subject to SEC regulations, quarterly reporting (10-Q), annual reports (10-K), and additional disclosures that benefit shareholders through increased transparency and oversight. Q13: How will the company use the capital raised from an IPO? A: While plans are still being finalized, proceeds from an IPO are typically used for product development, clinical trials, regulatory approvals, and scaling operations. Q14: When will I receive my new Rejuvenalt shares? A: After the merger becomes effective and once your Ecnalab membership units are formally surrendered, you will receive stock certificates or electronic registration of your Rejuvenalt shares. Users, Influencers & Shareholder Q&A: Section 2: WIMKIN Strategic Developments. GENERAL OVERVIEW Q1: What are the recent announcements from WIMKIN? A: WIMKIN has announced three major strategic developments: A strategic partnership with Stock Traders Daily Plans to go public A new privacy and monetization model offering users the ability to protect their data and enjoy an ad-free experience through a Secure Membership at $1.99/month STRATEGIC PARTNERSHIP Q2: What does the partnership with Stock Traders Daily involve? How do I get more information about Stock Traders Daily? A: The partnership aligns WIMKIN with Stock Traders Daily to enhance investor visibility, improve financial strategy, and support WIMKIN's growth as it moves toward a public offering. It also brings expertise in market communication and shareholder engagement. This partnership will allow WIMKIN users to access to stock research at HUGE discounts. SEE BELOW for more information on Stock Traders Daily. GOING PUBLIC (IPO) Q3: Is WIMKIN really going public? What does that mean? A: Yes. WIMKIN is preparing to go public, which means it intends to list its shares on a public stock exchange. This will give users and early shareholders the opportunity to trade their shares and participate in the company’s financial success. Q4: How will going public benefit users and shareholders? A: Liquidity: Shareholders will have the ability to sell or trade shares on the open market. Valuation: Public status may increase WIMKIN’s valuation and attract institutional investment. Resources: Funds raised will go toward platform development, influencer rewards, marketing, and security enhancements. Q5: When is the IPO expected to happen? A: A specific IPO date has not yet been announced. WIMKIN is currently preparing necessary steps including regulatory filings and corporate restructuring. DATA PRIVACY & MEMBERSHIPS Q6: What is the new membership model? A: Free Membership: Standard access to all WIMKIN features, with data shared to support advertising. Secure Membership ($1.99/month): No data sharing with third parties, ad-free browsing, and enhanced user privacy. Q7: Why introduce data sharing at all? A: Like most platforms, WIMKIN uses data sharing with third parties to support free access through advertising revenue. However, the Secure Membership option gives users full control and transparency over their data use. Q8: Can I opt out of data sharing? A: Yes. Users who choose the Secure Membership will opt out of all third-party data sharing while continuing to access all platform features—plus enjoy an ad-free experience. INFLUENCER MONETIZATION Q9: How does the influencer payment program work? A: Influencers on WIMKIN will receive $50 per month for every 5,000 friends or followers. This is WIMKIN’s way of recognizing and rewarding creators who share meaningful content and grow the platform’s reach. Q10: How do I qualify as an influencer? A: Any user with 5,000+ friends is eligible. Further details about verification and payment setup will be provided within the WIMKIN Creator Dashboard (coming soon). SHAREHOLDER QUESTIONS Q11: Who owns WIMKIN? A: WIMKIN is currently privately held, with ownership distributed among early users, platform contributors, and founding stakeholders. Q12: What will change for shareholders as WIMKIN goes public? A: Shares will become tradable, providing liquidity Company transparency will increase through public financial reporting Shareholder value is expected to increase as platform growth and monetization scale up Q13: How will these changes affect WIMKIN’s core mission? A: WIMKIN remains committed to free speech, user choice, and data control. These changes only strengthen its ability to grow responsibly while staying true to the values that built the platform. image Stock Traders Daily Executive Summary Stock Traders Daily’s AI-Driven Strategy Indicators for Outperformance and Risk Reduction Stock Traders Daily has been at the forefront of market strategy development for over 25 years, combining deep market expertise with advanced technology to deliver consistently effective investment solutions. Through our proprietary predictive artificial intelligence, we generate highly accurate market data that fuels a suite of disciplined, risk-conscious strategies—designed not only to outperform the S&P 500 (SPX), but to do so with significantly reduced volatility. Our time-tested approach prioritizes data accuracy, strategy integrity, and investor peace of mind. We’re not just experienced—we’re exceptionally good at what we do, and our long track record of success speaks for itself. Key Strategies and Results 1. CORE Portfolio Strategy Indicator Objective: Minimize volatility while generating steady returns. Approach: Uses SPY signals and transitions to cash to avoid downside risk. Performance: 5-Year Return: +60.64% 3-Year Beta: 0.14, Alpha: 1.13 ULTRA CORE: A leveraged version for those seeking higher returns with controlled risk. 2. Evitar Corte Strategy Indicator Objective: Anticipate and avoid market crashes using FOMC monetary policy as a key variable. Performance: Predicted major downturns including the Dot-Com Crash, 2008 Credit Crisis, and COVID-19 Crash. Outperformed the SPX by over 623% using a SPY-Cash model. Benefit: Simple yet powerful overlay for any investment strategy. 3. Stock of the Week (SOW) Strategy Objective: Capture short-term momentum in individual stocks highly correlated to the broader market. Approach: Enters a tactical position weekly and exits to cash over weekends. Performance: +660% outperformance vs. SPX since 2007. 3-Year Beta: 0.39 Key Strength: High-performance with built-in risk control through limited exposure. What Sets Us Apart 25 Years of Proven Expertise: A quarter-century of experience, adaptation, and success in all types of market conditions. Elite-Level Accuracy: Our predictive AI delivers precise market signals that form the foundation of our standout performance. Risk-Aware Philosophy: We aim to protect first, grow second—because avoiding losses is the most effective way to win long term. Strategy Flexibility: Our tools work across portfolio types and are excellent cash alternatives, as many of our strategies favor going to cash. Our Philosophy & Commitment At Stock Traders Daily, our foundational belief is simple: Accurate data begets accurate strategies. From the outset, our goal was to protect portfolios from severe downturns. The fact that our models also delivered substantial outperformance is a testament to the precision and power of our approach. We’ve spent 25 years refining what we do—and we’ve gotten very good at it. While no model can guarantee future returns, the strength of our process, the accuracy of our data, and the results we’ve consistently delivered set us apart as a trusted leader in data-driven portfolio strategy. “The successes we have had are rooted in the accuracy of our data. It makes creating effective strategies easier.” — Thomas H. Kee Jr., Strategy Architect, Stock Traders Daily

View Less